OrthoPediatrics Corp.

NASDAQ•KIDS

CEO: Mr. Mark C. Throdahl

セクター: Healthcare

業種: Medical - Devices

上場日: 2017-10-13

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products. Its products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail, PediLoc Tibia, ACL Reconstruction System, Locking Cannulated Blade, Locking Proximal Femur, Spica Tables, RESPONSE Spine, BandLoc, Pediguard, Pediatric Nailing Platform | Femur, Devise Rail, Orthex, The Fassier-Duval Telescopic Intramedullary System, SLIMTM Nail, The GAP Nail, The Free Gliding SCFE Screw System, GIROTM Growth Modulation System, PNP Tibia System, ApiFix Mid-C System, and Mitchell Ponseti. The company serves pediatric orthopedic market, as well as pediatric orthopedic surgeons and caregivers. OrthoPediatrics Corp. was founded in 2006 and is headquartered in Warsaw, Indiana.

連絡先情報

2850 Frontier Drive, Warsaw, IN, 46582, United States

574-268-6379

www.orthopediatrics.com

時価総額

$437.58M

PER (TTM)

-10.3

26.6

配当利回り

52週高値

$26.40

52週安値

$15.28

52週レンジ

18%

順位65Top 96.0%

1.6

F-Score

改良版 Piotroski 分析

10年ファンダメンタル

弱い • 1.6 / 9 ポイント

スコアレンジ (0-9)

8-9: 価値が優れている

6-7: 基礎体質が強い

4-5: 全体的に堅調

0-3: パフォーマンスが弱い

データ期間: 2016-2025

財務ダッシュボード

Q4 2025 データ

売上高

$61.61M+0.00%

直近4四半期の推移

EPS

-$0.43+0.00%

直近4四半期の推移

フリーCF

$9.75M+0.00%

直近4四半期の推移

2025 Annual 決算ハイライト

主なハイライト

Strong Annual Revenue Growth Total revenue reached 236.3M USD, up 15% from 204.7M USD in 2024, driven by strong performance in trauma and scoliosis segments.

Scoliosis Segment Expansion Scoliosis revenue reached 66.0M USD, up 20% from 55.2M USD in 2024, reflecting increased sales of RESPONSE and 7D technology systems.

Trauma Segment Performance Trauma and deformity revenue reached 166.3M USD, up 15% from 145.1M USD in 2024, representing 70% of total annual global revenue.

リスク要因

Persistent Operating Losses Net loss widened to 39.6M USD in 2025 from 37.8M USD in 2024, reflecting ongoing challenges in achieving and sustaining future profitability.

Regulatory Compliance Risks Extensive FDA and international regulations, including MDR certification, impose significant compliance costs and potential delays in product clearances or market access.

Third-Party Sales Reliance Reliance on independent sales agencies for 56% of global revenue creates risks if agencies fail to promote products or terminate business relationships.

Product Liability Exposure Potential product liability claims inherent in medical device sales could result in significant litigation costs, reputational damage, and decreased product demand.

見通し

Strategic Market Expansion Plans to deepen penetration in Brazil and Germany, leveraging new warehouses and legal entities to drive international growth and market share.

R&D Investment Focus Commitment to launch at least one new surgical system and multiple product line extensions annually to address unmet pediatric orthopedic needs.

Clinic Network Growth Continued focus on selective clinic acquisitions and greenfield expansion to strengthen O&P service offerings and improve patient access to specialized care.

同業比較

売上高 (TTM)

EHAB

$1.06B

+2.4%

VREX

$854.40M

+4.1%

AVNS

$701.20M

+1.9%

粗利益率 (最新四半期)

SMLR

91.5%

+0.1pp

LAB

83.5%

-3.2pp

TMCI

80.6%

-1.1pp

主要指標

銘柄コード	時価総額	PER (TTM)	ROE (TTM)	負債比率
CGEM	$796.94M	-3.6	-46.2%	0.6%
EHAB	$690.85M	-150.1	-0.8%	42.8%
AVNS	$636.63M	-9.4	-8.6%	12.0%

長期トレンド

直近4四半期

売上高

純利益

営業キャッシュフロー

4四半期売上高CAGR

5.5%

安定成長

4四半期純利益CAGR

N/M

収益構造の変化

キャッシュフロー安定性

25%

キャッシュフローに注意が必要

深度リサーチ

次回決算:2026年5月5日

EPS:-

売上高:-

財務データ

決算説明会

財務レポート

ニュース

損益計算書

バランスシート

キャッシュフロー計算書

財務比率

変化率

損益計算書	直近12ヶ月

データなし